Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHGV9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,901
Award facts
- Contract value 100% obligated
- $37,901.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $37,901.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The contract, issued on January 7, 2026, with an ultimate completion date of January 29, 2026, is structured as a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group will perform all work at its Park Ridge facility and will serve as the sole contractor with no identified subcontractor relationships.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to supply pharmaceutical products to Department of Defense medical facilities worldwide. The parent contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established performance across numerous delivery orders for diverse pharmaceutical products—including specialty biologics, oncology treatments, vaccines, and emergency medications—demonstrates the company's capability to fulfill the specialized pharmaceutical requirements supporting military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FHGV9?
SPE2DR26FHGV9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FHGV9 worth?
The government has obligated $37,901 on SPE2DR26FHGV9.
Is contract SPE2DR26FHGV9 an order under another contract?
Yes. SPE2DR26FHGV9 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGV9 competed?
The extent of competition for SPE2DR26FHGV9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award